

Study Protocol

Full title	A non-interventional, open observational non-inferiority study in two cluster-assigned cohorts of children aged 14 months into the safety of NeisVac-C® vaccines manufactured at two different production sites and given simultaneously with measles-mumps-rubella vaccine, assessed by web-based intensive monitoring
Short title	Web-based intensive safety monitoring of NeisVac-C® vaccination in toddlers
Study name	Peuterprik
Version	Version 1.4, 21 July 2015
EU PASS register	ENCePP SDPP/5937 Seal registered 17 March 2014
Active substances	ATC code for study product NeisVac-C® J07AH07, for concomitant product M-M-R-VaxPro® J07BD52
Product reference	Netherlands Marketing Authorisation Number of NeisVac-C®: RVG 26343
Procedure number	UK/H/0435/001
Marketing authorisation holders	NeisVac-C®: Pfizer Inc M-M-R-VaxPro®: Sanofi Pasteur MSD
Joint PASS	No
Research question and objectives	To compare the safety of the NeisVac-C® bulk material produced at Pfizer in Orth/Donau (new) (group A) with the material produced in Beltsville (old) (group B) in toddlers aged 14 months, administered simultaneously with MMR vaccine.
Country of study	The Netherlands
Protocol authors	Linda Härmark PhD, Hans Rümke MD PhD, Agnes Kant MPH PhD
Contact details	Netherlands Pharmacovigilance Centre Lareb Goudsbloemvallei 7 5237 MH 's-Hertogenbosch h.rumke@lareb.nl +31 73-64 69 700
Co-investigators and Advisors	Leontine van Balveren MSc, Lareb Jeanet Kemmeren MSc PhD, Epidemiology, RIVM Natasja Hoekstra MSc, DVP / IOD, RIVM Yvonne Wijnands MD, DVP Zuid, RIVM

Confidentiality Statement

The information provided in this document is the property of the Netherlands Pharmacovigilance Centre Lareb and is shared with you and your staff in confidence. This information should not be disclosed to others without written authorization from Lareb, except to the extent necessary to ensure adequate conduct of the study.

PROTOCOL SIGNATURE PAGE

Protocol details	
Study title:	A non-interventional, open observational non-inferiority study in two cluster- assigned cohorts of children aged 14 months into the safety of NeisVac-C® vaccines manufactured at two different production sites and given simultaneously with measles-mumps-rubella vaccine, assessed by web-based intensive monitoring
Study name:	Peuterprik

Name and role / function	Signature	Date
Agnes Kant Sponsor Director of Lareb		
Linda Härmark Principal Investigator Lareb		
Hans Rümke Coordinating Investigator Lareb		

PROTOCOL SYNOPSIS

STUDY TITLE	A non-interventional, open observational non-inferiority study in two cluster- assigned cohorts of children aged 14 months into the safety of NeisVac-C® vaccines manufactured at two different production sites and given simultaneously with measles-mumps-rubella vaccine, assessed by web-based intensive monitoring
STUDY NAME	Peuterprik
STUDY PRODUCT(S)	NeisVac-C®, Meningococcal Group C Polysaccharide Conjugate Vaccine Adsorbed, 'old' and 'new'
STUDY PHASE	Post marketing surveillance
STUDY OBJECTIVES	To compare the safety of the NeisVac-C® bulk material produced at Pfizer in Orth/Donau (new) (group A) with the material produced in Beltsville (old) (group B) in toddlers aged 14 months, administered simultaneously with MMR vaccine. Primary The primary endpoint is the proportions of subjects with fever reactions within 4 days after administration. Secondary The secondary endpoints are proportions of subjects with - solicited other systemic and local reactions within 4 days after administration - non-solicited other systemic and local reactions within 4 days after administration - non-solicited other systemic and local reactions from 5 to 28 days after administration
STUDY DESIGN	non-interventional, open observational non-inferiority study with two cluster- assigned cohorts
SUBJECTS	At least 2430 healthy toddlers aged 13-18 months old, eligible to receive MenC and MMR vaccinations according to the NIP
INCLUSION CRITERIA	- age 13-18 months old (boundaries included) - eligible to receive MenC and MMR vaccinations according to the NIP
EXCLUSION CRITERIA	- children receiving either MenC or MMR vaccine and not both at same time - children with parents that are not able or willing to understand or fill the questionnaires
STUDY PARAMETERS	Primary: reactogenicity defined as % of children with rectal temperature 38,0 Celsius and above during the first 4 days after vaccination Secondary: other solicited and unsolicited complaints and symptoms at injection site as well as systemic reactogenicity
STUDY GROUPS	Two study groups of similar size will be formed according to the MenC vaccination that has been given at the baby clinics, i.e. NeisVac-C® from either Orth/Donau (group A) or Beltsville (group B).
STUDY PRODUCT REGIME	Children receive one injection of either MenC vaccine while MMR vaccine is given at a different injection site simultaneously
STUDY PERIOD	2 years
STUDY DESCRIPTION	non-interventional, open observational non-inferiority study with two cluster- assigned cohorts
STATISTICAL ANALYSIS	The primary endpoint of the study, fever cases observed within 4 days after vaccination will be analyzed using logistic regression with vaccination groups ("old" / "new" product) and potential confounders as explanatory factors, applying a log link in order to obtain relative risk estimates at the end. Relative risk and its 95% CI of occurrence of fever cases with the "new" and "old" NeisVac-C® product will be calculated from the regression model assessing a potential increase of fever reactions with the "new" product. If the upper limit of the 95% CI is below 1.5 then the "new" product is considered to be non-inferior to the old one as far as fever reaction is concerned. The secondary endpoints will be analyzed similarly and descriptive without the non-inferiority considerations.
SPONSOR	Lareb

OVERVIEW OF PROTOCOL AMENDMENTS

Amendment 1, 29 July 2014

Amendment 1 includes the following changes

1. Inclusion of an amendment section in the protocol
2. Inclusion of reference to ENCePP seal
3. Additions relating to processing questionnaire data from parents who measured their child's temperature using non-rectal thermometry

Change 1 affects the general layout of the Protocol and the Table of Contents

Change 2 affects the Title Page

Change 3 affects the protocol at the following paragraphs:

1. 6.3: if temperature is being reported by parents, the questionnaire asks the parents to specify the method of recording the temperature: rectal / ear / other
2. 6.5 will be replaced to include multiple methods of temperature recording, and the conversion of non-rectally derived values in order to have one set of temperature data consisting of both rectally recorded values and corrected non-rectally recorded values.

Amendment 2, 21 July 2015

Amendment 2 includes the following changes

1. Changes related to changed ownership of study product NeisVac-C® from Baxter Ltd to Pfizer Inc
2. Changes related to extension of recruitment area of study subjects.
3. Changes related to update of recruitment material
4. Changes related to longer duration of study
5. Minor changes

Change 1 affects the protocol in multiple paragraphs

- throughout the protocol Baxter is changed into Pfizer where applicable: (title page, protocol synopsis, chapter 1 par 2, chapters 2.1, 3.3, 7.1, 10.2.2
- chapter 1, 2nd paragraph: background of study rewritten.

The old text reads:

NeisVac-C® is a product of Baxter Ltd. Due to a transfer of the manufacturing site of the drug substance from Baxter's facility at Beltsville, Maryland, USA to Baxter's facility at Orth/Donau, Austria, Baxter has applied for a Type II variation application (UK/H/0435/001/II/047/G) to allow release of Orth/Donau batches based on comparability to clinically qualified Beltsville batches to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) as the authority of the Reference Member State (RMS). Baxter was also requested by the MHRA to submit a Risk Management Plan (RMP) in which it should be considered how the safety and efficacy of the vaccine manufactured at the new Orth/Donau site would be actively monitored in comparison with the Beltsville vaccine. In particular it was asked to consider the extent to which there would be co-marketing of the vaccines and to specifically address batch traceability, the limitations of passive surveillance to evaluate relative reactogenicity and to formulate proposals to either overcome this or to conduct active surveillance to demonstrate comparable reactogenicity.

The new text reads

NeisVac-C® is a product of Pfizer Inc, and till 01MAY2015 owned by Baxter Ltd. Due to a transfer of the manufacturing site of the drug substance from former Baxter's facility at Beltsville, Maryland, USA to former Baxter's facility at Orth/Donau, Austria, Baxter has applied for a Type II variation application (UK/H/0435/001/II/048/G) to allow release of Orth/Donau batches based on comparability to clinically qualified Beltsville batches to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) as the authority of the Reference Member State (RMS). Baxter was also requested by the MHRA to submit a Risk Management Plan (RMP) in which it should be considered how the safety and efficacy of the vaccine manufactured at the new Orth/Donau site would be actively monitored in comparison with the Beltsville vaccine. In particular it was asked to consider the extent to which there would be co-marketing of the vaccines and to specifically address batch traceability, the limitations of passive surveillance to evaluate relative reactogenicity and to formulate proposals to either overcome this or to conduct active surveillance to demonstrate comparable reactogenicity. From May 2015 Pfizer Inc is owner of NeisVac-C® and has adopted all obligations related to this product including the full commitment to the present study.

- In addition: the correct number of the Type II variation application (UK/H/0435/001/II/048/G) was given (erroneously numbered UK/H/0435/001/II/047/G in the old text).

Change 2 affects the protocol at 8.2, 8.3

- 8.2: as a consequence of enlarging the study area the baby clinics of the new regions are added to the distribution list (appendix 2).
- 8.3. The following text is added:
At a process evaluation it was found that instead of a participation rate of 15-20% only 6% of children actually enrolled to the study despite multiple efforts to stimulate taking part. In January 2015 it was therefore decided to extend the study both in time and regions, in order to obtain the required numbers of subjects. Geographically, the basis of recruitment of 25.000 children annually is increased with 7300 from additional regions. In time, the study has a hard limit by the date of expiry of the last product manufactured at Beltsville, MAR2017.

Change 3 affects Appendix 1 of the protocol:

- the flyer used for recruitment was restyled and made easier to understand for parents. As per April 2015, Appendix 1 now includes the updated flyer.
- specific reference to Appendix 1 was made in 4.4, 6.2, 6.3

Change 4 affects the study timelines described in the protocol in 3.3

The old timelines were:

year	month	activity / step
2014	APR	delivery of the appropriate batches in the study area
2014	APR	sending letters to parents of eligible children, from start weekly letters
2014	MAY	first inclusions
2014	JUN	first fully completed questionnaires
2015	APR	last letters sent
2015	MAY	last inclusions
2015	JUN	last completed questionnaires
2015	SEP	final draft study report
2015	OCT	study report

The provisional new timelines are

year	month	activity / step
2014	APR	delivery of the appropriate batches in the study area
2014	APR	sending letters to parents of eligible children, from start weekly letters
2014	MAY	first inclusions
2014	JUN	first fully completed questionnaires
2016	MAR	last letters sent
2016	APR	last inclusions
2016	MAY	last completed questionnaires
2016	JUN	final draft study report
2016	SEP	study report

- second paragraph second sentence was deleted because it is no longer applicable.

Change 5 affects style and further includes minor issues:

- typing errors corrected in protocol synopsis, 4.4, 6.1, 7.1, 11.2
- title page Dutch name of Lareb changed into international name, including telephone number
- Lareb corporate style updated in header of protocol

old logo



new logo



ABBREVIATIONS

Term	Explanation
AE	Adverse events
CI	Confidence Interval
CRF	Case Report Form
DVP	Dienst Vaccinvoorziening en Preventieprogramma's (till 2013 termed Regionale Coördinatie Programmas RCP), i.e. regional vaccine distribution and registry (part of RIVM)
ENCEPP	European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
GCP	Good Clinical Practice
ICF	Informed Consent Form
ICH	International Conference on Harmonisation
ITT	Intention to treat
MenC	NeisVac-C® vaccine to prevent infections by meningococci group C
MHRA	Medicines and Healthcare products Regulatory Agency
MMR	M-M-R-VaxPro® vaccine to prevent measles-mumps-rubella
NIP	Netherlands/National Immunisation Programme
PP	Per protocol
RIVM	Rijksinstituut voor Volksgezondheid en Milieu (National Institute of Public Health and Environment)
RMP	Risk Management Plan
RMS	Reference Member State
RVP	Rijksvaccinatieprogramma (National Immunisation Programme)
SAE	Serious adverse events
s.d.	Standard deviation
SmPC	Summary of Product Characteristics
SSAR	Suspected Serious Adverse Reaction
SUSAR	Suspected Unexpected Serious Adverse Reaction

TABLE OF CONTENTS**TITLE PAGE****PROTOCOL SIGNATURE PAGE****PROTOCOL SYNOPSIS****OVERVIEW OF PROTOCOL AMENDMENTS****ABBREVIATIONS****TABLE OF CONTENTS****CHAPTER 1. INTRODUCTION**

1.1 Rationale for the study

CHAPTER 2. STUDY OBJECTIVES

2.1 Primary study objective

2.2 Secondary study objective(s)

CHAPTER 3. STUDY DESIGN

3.1 Study design

3.2 Study description

3.3 Duration of the study and milestones

CHAPTER 4. SUBJECTS

4.1 Study population

4.2 Inclusion criteria

4.3 Exclusion criteria

4.4 Subject recruitment

4.5 Instructions and technical assistance during the study

4.6 Subject discontinuation during the study

CHAPTER 5. STUDY PARAMETERS

5.1 Primary study parameter

5.2 Secondary study parameter(s)

5.3 Other parameters

CHAPTER 6. STUDY PROCEDURES AND ASSESSMENTS

6.1 Schedule per eligible participant

6.2 Procedures

6.3 Assessments / collection of data

6.3.1 *Preregistration and registration*6.3.2 *Questionnaire 1 (4 days after vaccination)*6.3.3 *Questionnaire 2 (14 days after vaccination)*6.3.4 *Questionnaire 3 (28 days after vaccination)*

6.4 Reminders

6.5 Measurements

CHAPTER 7. STUDY PRODUCTS

7.1 Description of study products

7.2 Description of route of administration and dosage

7.3 Preparation, packaging, labeling and storage

7.4 Product shipment, accountability and destruction

CHAPTER 8. STUDY GROUPS, RANDOMISATION AND (UN-) BLINDING

8.1 Study groups

8.2 Randomization and stratification

8.3 Study size and recruitment population.

8.4 (Un) blinding procedure

CHAPTER 9. STATISTICS

9.1 Statistical formulation of the study hypothesis

9.2 Sample size calculation

9.3 Analysis sets

9.4 Descriptive statistics

9.5 Comparability of study groups

9.6 Statistical methods for data analysis

CHAPTER 10. SAFETY REPORTING

- 10.1 Definitions
- 10.2 (Serious) Adverse Events handling
 - 10.2.1 *Recording of (S)AEs*
 - 10.2.2 *SAE reporting*
 - 10.2.3 *Follow-up of (S)AEs*
- 10.3 New relevant safety information

CHAPTER 11. ETHICAL CONSIDERATIONS

- 11.1 Basic principles and regulations
- 11.2 Ethics Committee
- 11.3 Informed Consent
- 11.4 Confidentiality of study data
- 11.5 Benefits and risks assessment
- 11.6 Incentives/Compensation for subjects
- 11.7 Insurance

CHAPTER 12. ADMINISTRATIVE ASPECTS AND PUBLICATION

- 12.1 Roles and responsibilities
- 12.2 Source data
- 12.3 Data handling
- 12.4 Criteria for premature termination of the trial
- 12.5 Publication policy

REFERENCES**APPENDICES**

- Appendix 1 Recruitment Letter / Flyer Lareb
- Appendix 2 Randomisation/Distribution Lists RIVM

CHAPTER 1. INTRODUCTION

1.1 Rationale for the study

NeisVac-C® is a meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate). The vaccine stimulates the immune system to produce antibodies against group C meningococcal bacteria, thereby preventing the development of meningitis/meningococcal disease. It is indicated for active immunisation of children aged 2 months and older, adolescents and adults, for the prevention of invasive disease caused by *Neisseria meningitidis* serogroup C.

NeisVac-C® is a product of Pfizer Inc, and till 01MAY2015 owned by Baxter Ltd. Due to a transfer of the manufacturing site of the drug substance from former Baxter's facility at Beltsville, Maryland, USA to former Baxter's facility at Orth/Donau, Austria, Baxter has applied for a Type II variation application (UK/H/0435/001/II/048/G) to allow release of Orth/Donau batches based on comparability to clinically qualified Beltsville batches to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) as the authority of the Reference Member State (RMS). Baxter was also requested by the MHRA to submit a Risk Management Plan (RMP) in which it should be considered how the safety and efficacy of the vaccine manufactured at the new Orth/Donau site would be actively monitored in comparison with the Beltsville vaccine. In particular it was asked to consider the extent to which there would be co-marketing of the vaccines and to specifically address batch traceability, the limitations of passive surveillance to evaluate relative reactogenicity and to formulate proposals to either overcome this or to conduct active surveillance to demonstrate comparable reactogenicity. From May 2015 Pfizer Inc is owner of NeisVac-C® and has adopted all obligations related to this product including the full commitment to the present study.

In The Netherlands Immunisation Programme NeisVac-C® is given to children of an age of about 14 months simultaneously with MMR vaccine. MMR is a live, attenuated virus vaccine, with a latency window of about 5 days for side effects that are associated with the replication of vaccine viruses. Any febrile reaction occurring during the first 4 days after administration of both vaccines, is more likely to be associated with NeisVac-C® than with MMR vaccine. Because of this co-administration, The Netherlands is a suitable country where reactogenicity of NeisVac-C® can be evaluated, compared to countries where NeisVac-C® is co-administered with non-live vaccines (as is the case with most other European countries).

We therefore will investigate systemic and local adverse events following NeisVac-C® and MMR administered simultaneously, with emphasis on the first 4 days after administration, and with subsequent follow-up during the remaining month.

CHAPTER 2. STUDY OBJECTIVES

2.1 Primary study objective

The primary objective of this study in children aged 14 months is:

- to compare the proportions of vaccinees with fever of $\geq 38^{\circ}\text{C}$ within 4 days after injections of the Pfizer NeisVac-C® vaccine bulk material produced in Orth/Donau (new, group A) or NeisVac-C® vaccine of which the bulk material was produced in Beltsville (old, group B), and simultaneous MMR vaccine for both groups of NeisVac-C® recipients.

2.2 Secondary study objective(s)

Secondary objective of this study is to investigate

- the safety profile with other parameters (solicited and non-solicited) within 4 days after simultaneous injections of either MenC, and MMR vaccines.
- the safety profile of these vaccines with non-solicited parameters from 5 to 28 days after injection.

CHAPTER 3. STUDY DESIGN

3.1 Study design

This is a non-interventional, open observational non-inferiority study with two cluster- assigned cohorts .

3.2 Study description

Toddlers (14 months old) will receive at vaccination centers NeisVac-C® vaccination with either

- "old" lots produced in Beltsville (group B), or
- "new" lots from Orth/Donau (group A), simultaneously with MMR vaccine.

From 4 full days after the vaccines were administered, parents will receive web-based questionnaires with questions about any ADRs that occurred after vaccination.

The 1st questionnaire is sent at day 5 and covers days 1, 2, 3 and 4.

The 2nd questionnaire will be sent after two weeks and covers days 5 to 14.

The 3rd questionnaire will be sent after four weeks and covers days 15 to 28.

Day numbers are defined as:

- Day 1: day of vaccination, e.g. Monday
- Day 2: 1st day after vaccination, e.g. Tuesday
- Day 3: 2nd day after vaccination, e.g. Wednesday
- Day 4: 3rd day after vaccination, e.g. Thursday = last day of fever counting for primary endpoint.
- Day 5: 4th day after vaccination, e.g. Friday

3.3 Duration of the study and milestones

The study will continue for a whole year, to cover all seasons, and multiple vaccine batches as supplied by Pfizer Inc. The duration of the study for each participant is approximately one month from vaccination.

Provisional timing of events (dependent on availability of study products and schedules of their delivery by RIVM).

year	month	activity / step
2014	APR	delivery of the appropriate batches in the study area
2014	APR	sending letters to parents of eligible children, from start weekly letters
2014	MAY	first inclusions
2014	JUN	first fully completed questionnaires
2016	MAR	last letters sent
2016	APR	last inclusions
2016	MAY	last completed questionnaires
2016	JUN	final draft study report
2016	SEP	study report

CHAPTER 4. SUBJECTS

4.1 Study population

Participants will be recruited from a regionally defined population of healthy children who are eligible to receive regular vaccinations with MenC and MMR vaccines according to the Netherlands Immunisation Programme.

In this study at least 2430 fully evaluable toddlers, aged 14 months, equally distributed between the 'old' and the 'new' MenC vaccine who are vaccinated with simultaneous MMR vaccine according to the Dutch Immunization Programme in clinics are required for Per Protocol analysis.

4.2 Inclusion criteria

- children 14 months old (age range 13-18 months; boundaries included) who receive the NeisVac-C® and MMR vaccination in one of the participating clinics according to the NIP

4.3 Exclusion criteria

- children receiving either MenC or MMR vaccine and not both at the same time
- children that have received simultaneously any other vaccine than MenC and MMR
- children that are vaccinated at baby clinics that do not participate in the study
- children whose parents/caretakers register for the study later than day 4 after vaccination.
- children with parents that are not able or willing to understand/fill the questionnaires in Dutch.

4.4 Subject recruitment

In the target region designated vaccination centers/baby clinics will be supplied with NeisVac-C® vaccines with either "old" lots produced in Beltsville or "new" lots from Orth/Donau.

Approximately one month before the scheduled vaccination (usually at age 14 months) the parents/caretakers of children in the target region, will receive a letter with information about the study (Appendix 1) and the possibility to already sign up for the study, both online and through a paper form.

At the baby clinic, following NeisVac-C® and MMR vaccination, parents will be asked to participate, and the information required for participation will be written down on the study flyer (specification of injection sites and batch number per vaccine). Based on information in the letter and subsequent flyer (Appendix 1), parents may decide to participate and register at the study web-page. Parental consent is considered a valid equivalent of a signature if they voluntarily ticked a box stating that they have understood all information and confirm their participation.

4.5 Instructions and technical assistance during the study

During the study, the parents may contact the Netherlands Pharmacovigilance Centre Lareb at any time through mail or telephone if they have any questions concerning the study, especially if technical assistance in filling the questionnaires is required.

4.6 Subject discontinuation during the study

The participant can withdraw from the study at any moment without stating a reason. If a questionnaire has not been completed after a reminder has been sent, the patient is considered lost to follow up and will not receive any further questionnaires. Discontinuation has no medical consequences for the participant.

CHAPTER 5. STUDY PARAMETERS

5.1 Primary study parameter

Proportions of children with fever (rectally measured body temperature of $\geq 38.0^{\circ}\text{C}$) within 4 days after vaccination with NeisVac-C® and MMR.

5.2 Secondary study parameter(s)

Proportions of children with solicited other systemic and local reactions within 4 days after vaccination with NeisVac-C® and MMR.

The occurrence of the following reactions will be asked actively:

Local (injection site) reactions at the NeisVac-C® and/or MMR injection site

- redness, warmth, pain, swelling, induration, blue, itch

General (systemic) reactions

- rash
- decreased appetite
- less sleeping
- listlessness
- sleepiness/somnolence
- vomiting
- diarrhea
- (febrile) seizures

In addition a free text field is available so that symptoms not listed above can be reported.

5.3 Other parameters

The following base line data will be asked, to demonstrate comparability of both study groups. The influence of these potentially confounding characteristics will be addressed in the analysis:

- gender
- weight
- length
- medical history
- house hold size
- daycare and kindergarten

CHAPTER 6. STUDY PROCEDURES AND ASSESSMENTS

6.1 Schedule per eligible participant

time	actor	activity
- 4 wks	RIVM/DVP	sending letter to parents in region with predefined baby clinics. The letter is with headings of RIVM, and sent by actor.
-4 wks to -1 day	parents	pre-registration at Lareb LIM site, with contact details and planned date of vaccination
Day 1	baby clinic	<ul style="list-style-type: none"> - give MenC and MMR vaccinations - remind parents to the study described in the letter that parents received earlier. - record vaccinations on the study letter from the parents, and recording as usual for adequate registration by RIVM/DVP.
Day 4	parents	latest possibility to register for study, confirmation of date of vaccination
Day 5	Lareb	send questionnaire 1, reminder at day 7
Day 14	Lareb	send questionnaire 2, reminder at day 16
Day 28	Lareb	send questionnaire 3, reminder at day 32
Day 36	Lareb	closure

6.2 Procedures

Vaccinations take place at the baby clinic / health center of the toddler. Prior to vaccination, the child health physician or nurse reviews the health status of the child to exclude any contra-indication for MenC and MMR vaccinations according to the guidelines of the National Immunisation Programme. These vaccinations are given to all eligible children, regardless of later (non)participation.

Health personnel at the baby clinic will record the vaccinations (name clinic, name and batch no of vaccine, date of vaccination) in the child health dossier, as well as on the vaccination cards, which are sent to the RIVM vaccination registry (DVP), as prescribed in the NIP.

After vaccination, parents are reminded to the letter that they received earlier (Appendix 1), and that they still may sign-up for the study with the use of a reporting code. If they intend to participate, baby clinic staff will record the vaccines given at that day, specifically batch numbers, and injection sites. The letter also contains a diary table, to be used by the parents as an aide-memoire, to record any health event that is to be filled in the electronic questionnaires.

Parents of children who have registered to participate will receive a web-based questionnaire at day 5 after the vaccines were administered with questions about any ADRs that occurred within 4 days of vaccination. A second questionnaire will be sent after two weeks, and a third after 4 weeks.

6.3 Assessments / collection of data

6.3.1 Preregistration and registration

Upon receipt of the first letter parents may pre-register for the study by reporting their email address and scheduled vaccination date. At this date, Lareb will send them an email with a link enabling the parents to register for the study.

After vaccination, parents are given a flyer with information about the study (Appendix 1), and how to sign-up for the study (web address and study specific access code).

The following data are requested.

- general data

1. are MenC and MMR vaccines administered both? If only one, or more than 2, vaccines were given, the child cannot further participate.
2. reporting code
3. date of vaccination
4. batch numbers of administered vaccines (to be recorded at baby clinic)
5. injection sites of administered vaccines (arm/leg/left/right) (to be recorded at baby clinic)
6. registration of email address. Per email address, only one child can participate. For more children in a household/family (twins, triplets,...) separate email addresses are required.
7. accept Lareb privacy rules yes/no. Only proceed if ticked: yes.

- data of reporting parent and child

1. confirm email address
2. child: date of birth
3. child: sex
4. child: height at time of vaccination
5. child: weight at time of vaccination
6. baby clinic: place and street address (choose from list).

- base line data

1. medical history, did your child have: ... (tick if applicable)
 - infections,
 - coughing/dyspnea,
 - skin rash,
 - hypersensitivity or allergy,
 - vomiting and/or diarrhea,
 - other: please specify ...,
 - none of the above.

- concomitant medication

1. Does your child use any medication: if yes: specify the medicine, dose, start date and stop date if applicable

6.3.2 Questionnaire 1 (4 days after vaccination)

Start question: did your child experience an adverse reaction/event: Y/N.

If N: have other medicines been used: click to add

If Y: which adverse events have occurred

- injection site reaction, if yes
 - o where did the reaction occur: one or both sites: specify arm/leg/left/right
 - o further questions per injection site
 - tick symptoms: red, warm, pain, swelling, indurated patch, blue, itch, other: please specify
 - size: largest possible diameter in centimeters (rounded upwards)
 - onset time after injection
 - treated, if yes specify
 - recovery status, if recovered: when
 - size will be categorised by diameter <2 cm: mild, 2-5 cm: moderate, >5 cm: severe
- fever, if yes
 - what was temperature (max value, rectally measured): __, __°C
 - how was temperature recorded: rectally / ear / other method; if other, specify
 - onset time after injection
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very
- skin rash
 - please describe ...,
 - onset time after injection
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very
- less appetite
 - onset time after injection
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very
- sleeping less
 - please describe ...,
 - onset time after injection
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very
- sleeping more/somnolence
 - onset time after injection
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very
- listlessness
 - onset time after injection
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very
- vomiting
 - onset time after injection
 - how often
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very
- diarrhea
 - onset time after injection
 - how often
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very

- (febrile) seizures
 - please describe:
 - what was temperature at the time of the seizure:
 - onset time after injection
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very
- other reactions (more than 1 additional unsolicited reaction can be added).
 - please describe:
 - onset time after injection
 - treated, if yes specify
 - recovery status, if recovered: when
 - impact as experienced by parents, graded as: not-mildly-moderately-very

For all events together it will be asked :

- was the child seen by a doctor for this complaint.
- did any of the reported events lead to one of the following:
 - o No, if Yes, tick if applicable:
 - hospitalisation
 - immediately life threatening
 - death

Any other data to label the reported AE as serious according to CIOMS criteria will be obtained from free text entries. They will be individually assessed by the Lareb investigator, and further regarded as SAE if applicable.

Co-medication:

- did your child have changes in medication.
Medication listed at Start are shown again and open for editing (start date, stop date, dose, add new)

Characteristics of the household

- how many children are living in your household (including the vaccinee):
choose from list: 1, 2, 3, 4, 5, 6 or more.
- does your child go to guest parents, daycare centre, kindergarten

Any reported complaints that are not resolved will be open to edit in next questionnaires. In addition, parents are asked to report new events if applicable. All new events are to be entered in a free text field, and will be manually coded.

6.3.3 Questionnaire 2 (14 days after vaccination)

- questions about any events that are open since questionnaire 1. Treatment, recovery and severity data: earlier entries can be changed.
- questions about any new unsolicited events that have started after completion of questionnaire 1, including any occurrence of fever.
- did your child have changes in medication

6.3.4 Questionnaire 3 (28 days after vaccination)

- questions about any events that are open since questionnaires 1 or 2
- questions about any new unsolicited events that have started after completion of questionnaire 2, including any occurrence of fever.
- did your child have changes in medication
- is your child healthy at present
- do you have any other remarks (contact form to be sent to email server; not part of the data collection of the study)
- thank you!

6.4 Reminders

Parents are sent reminders if the filled questionnaire is not received by Lareb.

- after Q1 (day 5), reminder at day 7, valid time of return: day 8
- after Q2 (day 14), reminder at day 16, valid time of return: day 18
- after Q3 (day 28), reminder at day 32, valid time of return: day 36.

Questionnaires received after the valid time of return will not be included in the Per Protocol analysis.

6.5 Measurements

If parents suspect their child to have fever, they are asked to measure body temperature rectally with their own thermometer. However, it appeared that many if not most parents use ear thermometers to measure temperature of their child. For the study, data will be analysed with values obtained by rectal recordings. Temperature values obtained otherwise will be corrected to make them comparable with rectally obtained temperature values. To temperature values obtained by ear thermometry, 0,3°C will be added, and to axillary temperature values 0,5°C will be added. These correction factors are based on literature on ear thermometry (1-7), and on a generally accepted correction rule for axillary recording. In case of another or unknown temperature recording method, the reported value will be used without further correction.

Several studies comparing rectal and ear thermometry show that these methods do not match completely, both with too high as too low values obtained by ear thermometry compared to rectally obtained values (1-7), and some explicitly state their preference for rectal measurements. We however have to adapt to current practice, because parents cannot be informed to do rectal measurements in their child.

Most publication give a mean difference between 0,2 and 0,3°C for both methods. Because we do not want to underscore ear obtained values, we will use a correction factor of +0,3°C.

Furthermore, we assume that any imprecision of recording and incomplete matching of temperature values obtained with different methods, will be similarly distributed over both groups of 'old' and 'new' vaccine recipients, and thus do not affect a correct comparison of these groups for the primary study parameter.

Additional references for amendment 1

1. Craig JV, Lancaster GA, Taylor S, Williamson PR, Smyth RL. Infrared ear thermometry compared with rectal thermometry in children: a systematic review. *Lancet* 2002;360:603-9.
2. Zhen C, Xia Z, Long L, Pu Y. Accuracy of Infrared Ear Thermometry in Children: A Meta-Analysis and Systematic Review. *Clin Pediatr (Phila)*. 2014 May 30. Pii: 0009922814536774. [Epub ahead of print]
3. Nimah MM, Bshesh K, Callahan JD, Jacobs BR. Infrared tympanic thermometry in comparison with other temperature measurement techniques in febrile children. *Pediatr Crit Care Med*. 2006 Jan;7(1):48-55.
4. El-Radhi AS, Patel S. An evaluation of tympanic thermometry in a paediatric emergency department. *Emerg Med J*. 2006 Jan;23(1):40-1.
5. Nordås TG, Leiren S, Hansen KS. Can ear temperature measurement be used in a hospital? [Article in Norwegian]. *Tidsskr Nor Lægeforen*. 2005 Oct 20;125(20):2763-5.
6. Robinson JL, Jou H, Spady DW. Accuracy of parents in measuring body temperature with a tympanic thermometer. *BMC Fam Pract*. 2005 Jan 11;6(1):3.
7. Gasim GI, Musa IR, Abdien MT, Adam I. Accuracy of tympanic temperature measurement using an infrared tympanic membrane thermometer. *BMC Res Notes*. 2013 May 10;6:194. Doi: 10.1186/1756-0500-6-194.

CHAPTER 7. STUDY PRODUCTS

7.1 Description of study products

All vaccines used in this investigation are regularly licensed products, currently used in the NIP. Their good record of safety and effectiveness is well established. For details of both products, see the SmPC.

NeisVac-C® vaccine is a suspension for injection in a pre-filled syringe of 0,5 ml. It is a conjugated meningococcal group C-polysaccharide vaccine (adsorbed). RVG number 26343. One dose (0,5 ml) contains *Neisseria-meningitidis* polysaccharide (O-deacetylated) of group C (C11-strain) 10 microgram conjugated to tetanus toxoid 10 – 20 microgram, adsorbed to aluminumhydroxide, hydrated 0,5 mg Al3+. The product further contains sodium chloride and water for injections.

Originally, NeisVac-C® was manufactured in USA. Former owner Baxter Ltd has decided to continue production in Austria. The change of production site was approved by EMA, as all in process tests and preclinical tests showed no deviations. License was continued, with the advice that a Post-Authorization Safety Study should be performed, which is the subject of the study described in this protocol.

Baby clinics are randomised and supplied with either product (new vs old production facility, product A vs product B).

Simultaneously, all children are given a MMR (measles-mumps-rubella vaccine, live attenuated).

M-M-R-VAXPRO® powder and solvent for suspension for injection. Measles-Mumps-Rubella vaccine (live). EMA number EU/1/06/337/001.

After reconstitution one dose (0,5 ml) contains:

- Measles virus¹ Enders' Edmonston strain (live, attenuated), no less than 1x10³ CCID50*
- Mumps virus¹ Jeryl Lynn™ [Level B] strain (live, attenuated), no less than 12,5x10³ CCID50*
- Rubellavirus² Wistar RA 27/3 strain (live, attenuated), no less than 1x10³ CCID50*

* 50% cell culture infectious dose.

¹ produced in chicken embryo cells. ² produced in WI-38 human diploid lung fibroblasts.

The vaccine may contain traces of recombinant human albumine (rHA). The vaccine contains traces of neomycine. The vaccine contains 14,5 mg sorbitol, and further sodium phosphate, potassium phosphate, sucrose, hydrolysed gelatin, Medium 199 with

Hanks salts, minimum essential medium Eagle (MEM), monosodium L-glutamate, phenol red, sodium bicarbonate, sodium chloride and hydrochloric acid to obtain desired acidity.

At present M-M-R-VaxPro® (Sanofi Pasteur MSD) is used in the NIP. Throughout the present study, it is foreseen that this vaccine is the only brand used. Children may receive any batch of the MMR vaccine, and are not vaccinated with specified batches.

7.2 Description of route of administration and dosage

NeisVac-C® will be injected intramuscularly (one dose is 0,5 ml). MMR will be injected subcutaneously (one dose is 0,5 ml, after reconstitution).

Injection sites are not prescribed in this protocol. The baby clinic personnel is asked to follow their usual practice. Neither the various organisations of child health care, nor the National Immunisation Programme prescribe the injection sites. After injection, baby clinic staff is asked to write down which vaccine is injected where, and which batch numbers were used. Parents are asked to enter these data into the questionnaires.

7.3 Preparation, packaging, labeling and storage

All study products are packed and labeled according to their license. They are further distinguished by their batch numbers. Transport and storage are done according to the standards of the NIP.

7.4 Product shipment, accountability

All baby clinics in the study region will receive only one batch ("old" or "new") of NeisVac-C® during the course of the study. Any next shipment to a baby clinic should ensure that the right batch is delivered. From these shipments, also children who do not participate, will receive their NeisVac-C® vaccinations.

For MMR vaccine, there is no preference for particular batches to be used per clinic.

Throughout the study period, the baby clinics will be (re)supplied regularly (every 2-3 months).

Accountability is not a requirement for this study. However, the number of doses per baby clinic is recorded as part of the usual administration and surveillance of the NIP.

It may occur rarely that vaccines from one baby clinic are transferred to another. Therefore we verify the batch numbers by asking the parents.

CHAPTER 8. STUDY GROUPS, RANDOMISATION AND (UN-) BLINDING

8.1 Study groups

The study comprises of two groups, according to the NeisVac-C® vaccine that has been given. The parents will not be informed which product (old vs new) their child has received.

8.2 Randomization and stratification

Central randomisation: baby clinics are randomly assigned to use either the old or the new NeisVac-C®. Shipments are done according to a distribution list, generated to randomly assign either batch to any participating baby clinic, to ensure that both groups are similar in size, and that local differences in confounding factors (e.g. concurrent infections, habits and attitudes towards vaccinations, ...etc) are balanced out.

RIVM/DVP will generate the distribution list, and will provide the baby clinics accordingly (Appendix 2).

8.3 Study size and recruitment population.

In order to evaluate 1215 children per group according to protocol (see paragraph 9.2) we need to recruit higher numbers of children. The following estimations are done to determine the population size to target for participation. With 1215 per group we need 2430 fully evaluable and complete datasets. We assume that 90% of data from an estimated 2700 respondents that have completed all questionnaires are evaluable. We assume that after starting the questionnaires 75% of responders will also complete the last questionnaire, thus giving an estimation of 3600 responding parents that start and agree to participation. Experience of RIVM indicates that about 40% of parents participate to a similar questionnaire proposal. However, to be sure to include the desired number of respondents we assume a lower percentage: 15-20%. Thus we assume that 18.000 to 24.000 parents need to be addressed for taking part in the investigation. In addition, to compensate for other interferences or loss, we intend to address 25.000 parents.

At a process evaluation it was found that instead of a participation rate of 15-20% only 6% of children actually enrolled to the study despite multiple efforts to stimulate taking part. In January 2015 it was therefore decided to extend the study both in time and regions, in order to obtain the required numbers of subjects. Geographically, the basis of recruitment of 25.000 children annually is increased with 7300 from additional regions. In time, the study has a hard limit by the date of expiry of the last product manufactured at Beltsville, MAR2017.

8.4 (Un) blinding procedure

Not applicable

CHAPTER 9. STATISTICS

9.1 Statistical formulation of the study hypothesis

The primary endpoint in this study is defined as the number of children with fever reactions within 4 days after vaccination with NeisVac-C®. Fever defined as rectally measured 38° Celsius or higher.

Kroesbergen et al found in a study following 863 Dutch children that fever occurred in 46 (5,3%; 95% CI 3,83-8,83) of children at day 0, 1 and/or 2. Fever at days 3 and 4 is not mentioned. A graph shows that the daily prevalence of fever is about max 3,5%. From day 5 the % of children with fever is rising to 19% at day 9 (ascribed to simultaneously given MMR vaccine).

Our primary endpoint is based on pooled daily presence of fever from days 0 to 4 after vaccination. Based on Kroesbergen et al we expect this to occur in about 6% of the children (95% CI 4,44-7,71, when 52/863 cases).

Baby clinics will be randomized to vaccinate with either product

- investigational new product Orth/Donau (Austria) = Active = Group A
- comparator old product Beltsville (US) = Reference = Group B

Randomisation procedure: to be described

9.2 Sample size calculation

For a non-inferiority approach the following assumptions and choices were made:

- null hypothesis: group A receiving the new product, has a higher prevalence of fever than children in group B. The risk ratio between group A and B is 1.5 or more.
- alternative hypothesis (one-sided): the risk ratio between group B and group A is less than 1.5.
- study groups equally sized (approximately)
- type 1 error alpha: rejection null hypothesis when it is actually true, is set at 0,025, one-sided (ICH E9)
- type 2 error beta: rejection null hypothesis, is set at 0,80
- clinically acceptable or meaningful difference between endpoints in group A and group B: risk ratio of 1.5 indicating a higher risk of fever in group A (corresponding with a fever prevalence of 9% in group A).
- sample size is calculated to obtain numbers needed for the Per Protocol Analysis set.

Prior data indicate that the prevalence of fever among the reference group B is about 6%. Sample size was calculated using a web-based sample size calculator Sealed Envelope, based on Blackwelder. We will need to study 1215 children in each group to be able to reject the null hypothesis that the fever rates between in group A are higher than in group B, with probability (power) of at least 0,8. The type I error probability associated with this test of this null hypothesis is 0,05 (two-sided, 0.025% one-sided). If there is truly no difference in fever prevalence between the two groups, then 2430 children are required to be 80% sure that the upper limit of a one-sided 97.5% confidence interval (or equivalently a 95% two-sided confidence interval) of the risk ratio will exclude a difference in favour of the reference group of more than 3%.

9.3 Analysis sets

Participants that violate the protocol are excluded from the Per-Protocol Analysis Set. Protocol violations involve:

- not fulfilling criteria for inclusion and exclusion
- major deficiencies / discrepancies in the completion of questionnaire 1.
- non-adherence to pre-specified timelines.
- any concomitant vaccinations and other potential confounder that may interfere with the reactogenicity under study, or with the interpretation of the data.

As the electronic questionnaires enforce most criteria above, in the majority of cases decisions to exclude from the PPA data set are done automatically.

9.4 Descriptive statistics

Descriptive characteristics will be presented per study group, as numbers and/or proportions of children with an applicable parameter per group. The results will be displayed per group. For continuous variables, data will be presented as mean \pm SD (confidence interval) and proportions, and median (range). For binary variables data will be presented as n/N (%), and 95% CI. The secondary endpoints will only be descriptively analysed.

9.5 Comparability of study groups

Both study groups should be comparable for baseline characteristics and potential confounders, as defined in Chapter 5.

9.6 Statistical methods for data analysis

The primary endpoint of the study, fever cases observed within 4 days after vaccination will be analyzed using logistic regression with vaccination groups ("old" / "new" product) and potential confounders as listed in 5.3 as explanatory factors, applying a log link in order to obtain relative risk estimates at the end. Relative risk and its 95% CI of occurrence of fever cases with the "new" and "old" NeisVac-C® product will be calculated from the regression model assessing a potential increase of fever reactions with the "new" product. If the upper limit of the 95% CI is below 1.5 then the "new" product is considered to be non-inferior to the old one as far as fever reaction is concerned.

The secondary endpoints will be analyzed similarly and descriptively without the non-inferiority considerations.

CHAPTER 10. SAFETY REPORTING

10.1 Definitions

All symptoms, reported by the parents occurred during the study period will be considered as adverse event.

A *Serious Adverse Event* (SAE) is any untoward medical occurrence or effect that at any dose:

- results in death
- is life-threatening (at the time of the event)
- requires hospitalisation or prolongation of existing inpatients' hospitalisation
- results in persistent or significant disability or incapacity
- is otherwise medically important.

A SAE is defined as a *Suspected Serious Adverse Reaction* (SSAR) if it is:

- judged to be at least possibly related to the study product by investigator.
- expected (listed in the Summary of Product Characteristics).

A SAE is defined as a *Suspected Unexpected Serious Adverse Reactions* (SUSARs) if it is:

- judged to be at least possibly related to the study product by either investigator or sponsor, and
- unexpected (not listed in the SmPC).

The following events are not regarded as SAE:

- Hospitalisation that was already planned or anticipated before participation to the study.
- Any SAE occurred before vaccination.

However, prolongation of these hospitalisations due to complications or other aspects mentioned in the definition of an SAE must be handled as an SAE.

10.2 (Serious) Adverse Events handling

10.2.1 Recording of (S)AEs

In case of an SAE, the event will be transferred to the current Spontaneous Reporting System: the case will be entered in the Lareb database, and will be reviewed and processed as a regular report with the exception that it will not be forwarded to Eudravigilance.

10.2.2 SAE reporting

The content of filled questionnaires, including any reported non-serious and serious events, will be transferred electronically to Pfizer Inc on a weekly basis, after coding by a Lareb investigator.

Serious AEs are reported to Pfizer within 2 business days or 4 calendar days if a weekend is included. Potential signals will be reported within 3 business days or within 5 calendar days if a weekend is included.

10.2.3 Follow-up of (S)AEs

All SAEs are followed by Lareb until they have abated, or until a stable situation has been reached. This will be done according to the usual Lareb standards.

10.3 New relevant safety information

The investigator will inform the parents of the toddlers, the authorities including the National Public Health Institute responsible for the National Immunisation Programme, and the applicable manufacturers if anything occurs that may negatively affect the burden or risks of participation as foreseen in the research proposal. The study may be suspended pending further review by the Lareb Scientific Advisory Board, provided that suspension does not jeopardise the toddlers' health. Lareb will take care that parents of all participating toddlers are kept informed.

CHAPTER 11. ETHICAL CONSIDERATIONS

11.1 Basic principles and regulations

The study team must ensure that this study is conducted in full conformance with the principles of the 'World Medical Association Declaration of Helsinki' (18th WMA General Assembly, Helsinki, Finland, June 1964, with last amendments by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013), ICH guidelines for Good Clinical Practice as appropriate to pharmaceutical products, and local legislation of the country in which the research is conducted, whichever affords the greater protection to the individual.

11.2 Ethics Committee

This protocol and any accompanying informational material provided to the parents of the toddlers, will be submitted to the applicable Ethics Committee by the investigator according to local legislation. The Ethics Committee will firstly decide whether the proposed study fulfills criteria that necessitates a full review according to the Netherlands law on Investigations in humans (WMO). If so, approval from the Ethics Committee must be obtained before starting the study. Approval should be documented in a letter to the investigator specifying the date on which the Ethics Committee met and granted the approval, the composition of the Ethics

Committee, and version and date of all submitted documents. If a formal review is not required for this non-invasive, non-interventional questionnaire based study, the Ethics Committee is asked for a Waiver letter.

11.3 Informed Consent

Prior to study enrolment, no written informed consent is obtained from the parents of each toddler. Instead, based on the information in the letter and/or flyer, they report themselves to participate by giving their email address, and by agreeing to the Lareb privacy policy.

11.4 Confidentiality of study data

The investigator is responsible for treating subject and study information as confidential. The investigator should ensure that the subject identity will not be made publicly available. All subject study records are identified only by the subject identification number to maintain subjects' confidentiality. Identification codes lists that link the subjects' names to the subjects' identification number must be stored in the Investigator Site File.

11.5 Benefits and risks assessment

No known or potential risks are expected from the use of the study products, other than those applicable for the national Immunisation Programme.

11.6 Incentives/Compensation for subjects

Neither parents nor toddlers will receive a financial or other compensation for their participation in the study.

11.7 Insurance

Not applicable.

CHAPTER 12. ADMINISTRATIVE ASPECTS AND PUBLICATION

12.1 Roles and responsibilities

During the study a study team will be available on telephone to assist parents in filling the questionnaires.

12.2 Source data

All information obtained during the study will be directly recorded in an electronic database. Manually coded entries from free text field can be verified.

12.3 Data handling

All study data are kept on the central Lareb server. Backups are made daily.

Investigators are mandated to

- edit data if they are redundant,
- to code reactions according to MedDRA terminology from free text field

A data trail is formed by logging any changes.

12.4 Criteria for premature termination of the study

The study may be terminated as signals arise that would make continuation unsafe. As the vaccines under study are in general use, such situation may also have consequences beyond the scope of the study and its participants.

12.5 Publication policy

Lareb is free to publish any data obtained from the study. Results of the study will be published in a scientific journal.

REFERENCES

1. Kroesbergen HT, Moret-Huffmeijer L, Vermeer-de Bondt PE. Verschijnselen na gelijktijdige BMR- en meningokokken-C vaccinatie. Tijdschr Soc Geneesk 2005;83:425-431 (article in Dutch, non-PubMed)
2. ICH E9 Statistical Principles for Clinical Trials.
3. Sealed Envelope Ltd.: Randomisation and online databases for clinical trials. London, London, UK. <https://www.sealedenvelope.com/>
4. Blackwelder WC. "Proving the Null Hypothesis" in Clinical Trials. Control. Clin. Trials 1982;3:345-353.